Following technical review and Greater Manchester-wide consultation, the GMMMG neuropathic pain guidance has been updated and is now available on the Clinical Guidance and Pathways page. The formulary has also been updated to reflect the guidance.
Category: GMMMG
Neuropathic pain guidance updated
Formulary and subgroup decision updates
Following the May meeting of GMMMG, the website and formulary have been updated to reflect decisions made by GMMMG and the Clinical Reference Group (CRG). This includes:
- Bempedoic acid: GREEN following specialist advice (previously specialist initiation)
- Sotrovimab for COVID-19: RED
- Liraglutide for obesity in people aged 12-17: Do Not Prescribe
- Dupilumab for severe asthma: RED
- Belimumab for SLE: RED
- Cenobamate for epilepsy: GREEN following specialist initiation (by a tertiary epilepsy service)
- Risdiplam for spinal muscular atrophy: RED
- Solriamfetol for narcolepsy: RED
- Fostamatinib for chronic ITP: Do Not Prescribe
The formulary has also been updated to reflect relevant NICE guidelines and safety alerts. For full details of the changes, please see the Formulary Change Log and GMMMG decision summaries.
Formulary and subgroup decision updates
Following the February meeting of GMMMG, the formulary has been updated to reflect decisions made by the Clinical Reference Group (CRG) and Medicines and Guidelines Subgroup (MGSG). Changes include:
- Addition of NICE guidance and MHRA drug safety updates to formulary
- Duloxetine 90mg and 120mg capsules added to grey list as a GREEN drug
- Insulin degludec added to grey list as a GREEN (specialist initiation) drug
- Isoniazid for tuberculosis prophylaxis in renal patients added to RAG list as GREEN (specialist initiation)
- Dapsone 50mg and 100mg tablets for PCP prophylaxis added to RAG list as GREEN (specialist initiation)
For full details of the changes, please see the Formulary Change Log.
Formulary and subgroup decision updates
Following the November meeting of GMMMG, the formulary has been updated to reflect decisions made by the Clinical Reference Group (CRG) and Medicines and Guidelines Subgroup (MGSG). Changes include:
- Addition of NICE technology appraisals and MHRA drug safety updates to formulary
- Ustekinumab dose escalation in inflammatory bowel disease commissioning statement updated to include latest evidence
For full details of the changes, please see the Formulary Change Log.
Updated guidance: COPD management plan
Following GM-wide consultation, the Greater Manchester COPD guidance has been updated and is available from the clinical guidance and pathways page. The accompanying inhaler guide is under review and will be updated shortly.